Disparities in Castration-Resistant Prostate Cancer Trials
- 1 April 2015
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (10), 1101-1103
- https://doi.org/10.1200/jco.2014.58.1751
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Enzalutamide in Metastatic Prostate Cancer before ChemotherapyThe New England Journal of Medicine, 2014
- Five National Cancer Institute–designated cancer centers' data collection on racial/ethnic minority participation in therapeutic trialsCancer, 2014
- Annual Report to the Nation on the status of cancer, 1975‐2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancerCancer, 2013
- Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers ProgramCancer, 2013
- Project Data Sphere to Make Cancer Clinical Trial Data Publicly AvailableJNCI Journal of the National Cancer Institute, 2013
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerThe New England Journal of Medicine, 2013
- A systematic review of the factors influencing African Americans' participation in cancer clinical trialsContemporary Clinical Trials, 2013
- New developments in the management of prostate cancer.Journal of the National Comprehensive Cancer Network, 2013
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyThe New England Journal of Medicine, 2012
- Abiraterone and Increased Survival in Metastatic Prostate CancerThe New England Journal of Medicine, 2011